An Investigational Scan (hpMRI) for Monitoring Treatment Response in Patients With Thyroid Cancer Undergoing Radiation Therapy and/or Systemic Therapy

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This trial investigates whether hyperpolarized magnetic resonance imaging (hpMRI) can predict treatment response in patients with thyroid cancer undergoing radiation therapy and/or receiving systemic therapy before surgery. An hpMRI is like a standard MRI but involves the use of an imaging contrast agent called hyperpolarized 13-C-pyruvate. Diagnostic procedures, such as hpMRI, may predict a patient's response to treatment and may help plan the best treatment.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: M.D. Anderson Cancer Center
• Collaborator: National Cancer Institute (NCI)

Criteria

Inclusion Criteria:

• Be willing and able to provide informed consent

• Be informed of the investigational nature of this study

• Be diagnosed with thyroid cancer with intent for treatment

Exclusion Criteria:

• Have a history of severe claustrophobia

• Have electrically, magnetically or mechanically activated implants that would preclude magnetic resonance imaging (MRI)

• Have a history of cardiac arrhythmia

• Have an allergy to Gadavist intravenous contrast

• Estimated glomerular filtration rate (eGFR) < 30

• If female, be pregnant or breast feeding at time of consent